Impact of DYSIS by Experience Level of Colposcopist
In an article that was recently published in Gynecologic and Obstetric Investigation, Dr Coronado from the Hospital Clínico San Carlos in Madrid, Spain, presents and analyzes the data from a survey he performed among 63 colposcopists, using images from 50 colposcopic examinations that he had performed in his clinic.
Aiming to study the difference in colposcopic accuracy among physicians of varying experience and study the effect of including the DYSISmap as an adjunct to their colposcopic assessment, Dr Coronado divided the participants by level of experience into three groups (low, medium high) and measured their accuracy in predicting the outcome (Normal, CIN1, CIN2+) of each case as confirmed by biopsy.
The article can be found at http://www.karger.com/Article/Abstract/365087
For more information, please contact:
DYSIS Medical Ltd Tel: +44 (0)1506 592159
Alastair Atkinson, CEO
Notes to Editors
DYSIS Medical Ltd
DYSIS Medical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com
The DYSIS product employs advanced photonics and computer assistance to quantify and map the cervix during the aceto-whitening process. The product is CE marked and commercially available in Europe. It is also cleared to market in the USA by the FDA under the 510(k) programme as a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy.